
FDA Approved Icotyde, Taking the Top Psoriasis Target From Injection to Pill
The March 17, 2026 approval of icotrokinra blocks the IL-23 pathway orally. What patients should weigh on efficacy, monitoring, and coverage.
Sector news category — verified health events only (FDA, guidelines, major studies)

The March 17, 2026 approval of icotrokinra blocks the IL-23 pathway orally. What patients should weigh on efficacy, monitoring, and coverage.

The February 20, 2026 approval of milsaperidone adds a fresh side-effect profile to a class dominated by generics. What it means for patients and payers.

A January 5, 2026 announcement tied to a presidential memorandum set off schedule changes, court challenges, and a postponed ACIP meeting. What parents should know.

The January 12, 2026 approval of copper histidinate gives infants with the rare ATP7A disorder a standardized, FDA-reviewed treatment option.